Encore Medical aims to raise $17.25M in IPO funding for FDA heart device trials. Click here to read the latest analysis on ...

- Patent Foramen Ovale (PFO) Closure Devices Market size is expected to rise by 2026 owing to increasing prevalence, escalating preferences for minimally-invasive, safety, technically feasible ...

Abbott announced that the FDA has approved its patent foramen ovale occlusion system for patients with a PFO and prior stroke at risk for recurrent ischemic stroke. According to a company press ...

It has been well established that device closure has, on average, prevented stroke recurrence in people who’ve had patent foramen ovale–associated stroke, but a meta-analysis has drilled down into ...

Global PFO Closure Device Market Size was estimated at USD 121.53 million in 2021 and is projected to reach USD 208.00 million by 2028, exhibiting a CAGR of 7.98% during the forecast period. “PFO ...

While other device-based closures have demonstrated notable rates of atrial fibrillation (5.7–6.6%) and device-related adverse events, the NobleStitch™ system's fully suture-mediated approach ...

Because the benefits of patent foramen ovale closure were once in question, physicians remain hesitant about its use in clinical practice. Recent data, however, have confirmed the safety and efficacy ...

The population of patients undergoing patent foramen ovale (PFO) closure in the US doesn’t match those of the clinical trials that formed the basis of the US Food and Drug Administration’s approval of ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

Dan Kenny first started feeling a little off at the end of an otherwise normal workday in February 2023. "I kept telling myself, I'm going on this big trip, maybe I'm just a little tired and hadn't ...